{"id":125,"date":"2021-07-08T09:46:26","date_gmt":"2021-07-08T09:46:26","guid":{"rendered":"https:\/\/isosolution-v2.staging.xiyx.ai\/news\/https-isosolutions-com-wp-content-uploads-2021-07-psma-11-pet_ct-versus-choline-pet_ct-pdf\/"},"modified":"2026-09-04T19:48:39","modified_gmt":"2026-09-04T19:48:39","slug":"https-isosolutions-com-wp-content-uploads-2021-07-psma-11-pet_ct-versus-choline-pet_ct-pdf","status":"publish","type":"iso_news","link":"https:\/\/isosolution-v2.staging.xiyx.ai\/fr\/news\/https-isosolutions-com-wp-content-uploads-2021-07-psma-11-pet_ct-versus-choline-pet_ct-pdf\/","title":{"rendered":"PSMA-11-PET\/CT versus choline-PET\/CT pour guider la radioth\u00e9rapie ablative st\u00e9r\u00e9otaxique pour l'arr\u00eat du traitement de la privation d'androg\u00e8ne chez les patients atteints d'un cancer de la prostate oligomatastatique"},"content":{"rendered":"<p><strong>ABSTRATE<\/strong><\/p>\n<p>Contexte: Chez les patients atteints d'un cancer de la prostate r\u00e9current oligomatastatique, le traitement standard est le traitement de privation d'androg\u00e8ne (TAA). Cependant, l'ADT a de nombreux effets secondaires potentiels qui peuvent nuire \u00e0 la qualit\u00e9 de vie. Il est de la plus haute importance de proc\u00e9der \u00e0 une identification pr\u00e9coce pour s\u00e9lectionner les patients qui conviennent \u00e0 la radioth\u00e9rapie ablative st\u00e9r\u00e9otaxique (SABR) afin de pr\u00e9venir ou de retarder le d\u00e9but du THA et ses effets secondaires. <\/p>\n<\/p>\n<p>Parce que la Tomographie d'\u00e9mission de Positron Antigen-11 (PSMA-11-PET) a une sensibilit\u00e9 plus \u00e9lev\u00e9e que celle de la choline-PET, nous supposons que la SABR bas\u00e9e sur la PSMA-11-PET entra\u00eene une dur\u00e9e de r\u00e9ponse plus longue et un retard ult\u00e9rieur plus long dans le d\u00e9marrage de la TAA que la choline-PET.<\/p>\n<p><strong>M\u00c9THODES <\/strong><\/p>\n<p>Patients with oligometastatic (\u22644 metastases) recurrent prostate cancer (with no local recurrence) based on PSMA-11-PET or choline-PET treated with SABR from January 2012 until December 2017 were included. Primary endpoint was ADT-free survival. Secondary endpoints were Prostate Specific Antigen (PSA) response after SABR and time to PSA rise after SABR.<br \/>R\u00e9sultats : Cinquante patients (n = 40 PSMA-11-PET et n = 10 choline-PET) avec au total 72 l\u00e9sions ont \u00e9t\u00e9 inclus. Le suivi m\u00e9dian a \u00e9t\u00e9 de 24,3 mois. La PSMA-11-PET a permis d'assurer l'admissibilit\u00e9 des patients pr\u00e9sentant des taux de PSA inf\u00e9rieurs \u00e0 ceux de la choline-PET (m\u00e9diane 1,8 versus 4,2 ng\/mL, p = 0,03). Le groupe PSMA-11-PET avait une dur\u00e9e de r\u00e9ponse significativement plus longue (entre 34,0 mois (95%, intervalle de confiance (IC), 16,0\u201352,0) et 14,7 mois (95%, IC 4,7\u201324,7), p = 0,004) avec une survie plus longue sans TAA (entre 32,7 mois (95%, IC, 20,8\u201344,5) et 14,9 mois (95%, IC, 5,7\u201324,1), p = 0,01).<\/p>\n<\/p>\n<p class=\"has-text-align-center\">\n<\/p>\n<p><strong>CONCLUSIONS<\/strong><\/p>\n<p>Avec la PSMA-11-PET, nous sommes en mesure de s\u00e9lectionner les patients atteints d'un cancer de la prostate r\u00e9current oligomatastatique appropri\u00e9 pour le SABR \u00e0 un stade ant\u00e9rieur de la maladie \u00e0 des taux de PSA inf\u00e9rieurs. Le SABR guid\u00e9 par PSMA-11-PET a entra\u00een\u00e9 une dur\u00e9e de r\u00e9ponse significative plus longue et une survie sans ADT par rapport \u00e0 la choline-PET et peut donc pr\u00e9venir ou retarder les effets ind\u00e9sirables li\u00e9s \u00e0 l'ADT.<\/p>\n<p><a href=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\" data-type=\"URL\"><\/a><a rel=\"noreferrer noopener\" href=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\" data-type=\"URL\" data-id=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\" target=\"_blank\">Lire <\/a><a href=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\" data-type=\"URL\" data-id=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\">des <\/a><a rel=\"noreferrer noopener\" href=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\" data-type=\"URL\" data-id=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\" target=\"_blank\">pleine <\/a><a href=\"https:\/\/isosolutions.com\/wp-content\/uploads\/2021\/07\/PSMA-11-PET_CT-versus-choline-PET_CT.pdf\" data-type=\"URL\" data-id=\"https:\/\/isosolutions.com\/wp-content\/uploads\/2021\/07\/PSMA-11-PET_CT-versus-choline-PET_CT.pdf\">objet<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>ABSTRACT Background: In patients with oligometastatic recurrent prostate cancer, standard treatment is androgen deprivation therapy (ADT). However, ADT has many potential side effects that may result in impaired quality of life. Early identification to select patients suitable for stereotactic ablat<\/p>","protected":false},"featured_media":126,"template":"","iso_news_section":[43],"class_list":["post-125","iso_news","type-iso_news","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/fr\/wp-json\/wp\/v2\/iso_news\/125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/fr\/wp-json\/wp\/v2\/iso_news"}],"about":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/fr\/wp-json\/wp\/v2\/types\/iso_news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/fr\/wp-json\/wp\/v2\/media\/126"}],"wp:attachment":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/fr\/wp-json\/wp\/v2\/media?parent=125"}],"wp:term":[{"taxonomy":"iso_news_section","embeddable":true,"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/fr\/wp-json\/wp\/v2\/iso_news_section?post=125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}